Corient Private Wealth LP Grows Position in Insulet Corporation $PODD

Key Points

• Corient Private Wealth increased its Insulet position by 24.6% in the second quarter, purchasing 16,690 additional shares and bringing its holdings to 84,673 shares valued at approximately $12.9 million.
• Insulet reported quarterly EPS of $1.66, beating estimates of $1.47, while revenue reached $801.7 million and rose 23.5% year over year.
• Analyst sentiment is mixed: the stock has a consensus “Hold” rating and a $195.40 price target, while shares recently traded at $139.24—well below their one-year high of $354.88.

Corient Private Wealth LP boosted its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 24.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 84,673 shares of the medical instruments supplier's stock after purchasing an additional 16,690 shares during the period. Corient Private Wealth LP owned about 0.12% of Insulet worth $12,891,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Amundi boosted its holdings in Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier's stock valued at $77,320,000 after acquiring an additional 60,929 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Insulet in the second quarter worth $1,577,000. Vancity Investment Management Ltd increased its stake in Insulet by 34.6% in the second quarter. Vancity Investment Management Ltd now owns 2,866 shares of the medical instruments supplier's stock worth $436,000 after purchasing an additional 737 shares during the period. HB Wealth Management LLC increased its stake in Insulet by 33.4% in the second quarter. HB Wealth Management LLC now owns 4,298 shares of the medical instruments supplier's stock worth $654,000 after purchasing an additional 1,077 shares during the period. Finally, Saudi Central Bank lifted its position in shares of Insulet by 86.7% during the second quarter. Saudi Central Bank now owns 4,849 shares of the medical instruments supplier's stock worth $738,000 after purchasing an additional 2,252 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PODD shares. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Insulet in a research note on Tuesday, June 23rd. They set a "buy" rating and a $190.00 target price for the company. BTIG Research cut shares of Insulet from a "buy" rating to a "neutral" rating in a research report on Thursday, August 6th. Weiss Ratings downgraded shares of Insulet from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, June 24th. The Goldman Sachs Group restated a "buy" rating and issued a $205.00 target price on shares of Insulet in a research note on Wednesday, May 27th. Finally, Benchmark decreased their price target on shares of Insulet from $250.00 to $185.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $195.40.

Insulet Trading Up 1.0%

NASDAQ:PODD opened at $139.24 on Wednesday. The firm has a 50-day simple moving average of $151.47 and a 200-day simple moving average of $171.87. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The firm has a market cap of $9.66 billion, a P/E ratio of 26.03, a P/E/G ratio of 1.09 and a beta of 1.08. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company's quarterly revenue was up 23.5% on a year-over-year basis. During the same period last year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.